You are here

Article Text

Article menu
Download PDFPDF
Rare disease
CASE REPORT
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab
  1. Ziyang Liu,
  2. Merry Markham and
  3. Molly W Mandernach
  1. Department of Medicine, Division of Hematology/Oncology, University of Florida, Gainesville, Florida, USA
  1. Correspondence to Dr Ziyang Liu, ziyang.liu{at}medicine.ufl.edu

Abstract

A 46-year-old man presented with splenomegaly, abdominal adenopathy and profoundly elevated prothrombin time and partial thromboplastin time. He was diagnosed with marginal zone lymphoma (MZL) and small lymphocytic lymphoma, and the abnormal coagulation studies were secondary to the presence of a lupus anticoagulant. Optimal upfront therapy for MZL has not been established, and the incidence of antiphospholipid antibodies (APLA) in this patient population is rare. Following treatment with six cycles of bendamustine and rituximab with 2 years of rituximab maintenance, our patient remained in remission and his coagulation studies normalised. This report describes a case of successful treatment of APLA associated with MZL that resolved after treatment of the lymphoma.

  • malignant and benign haematology
  • chemotherapy

https://doi.org/10.1136/bcr-2018-224636

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors ZL- Responsible for reviewing patient clinical history and data, planning and writing of the case report. MM - Responsible for proofreading and editing oncologic portions of the article. MWM- Responsible for proofreading and editing the benign hematology portions of the article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests Not required.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.